Foreword |
|
vii | |
|
Preface |
|
ix | |
Contributors |
|
xxi | |
|
Clinical Point-of-Care Testing for Drugs of Abuse |
|
|
1 | (10) |
|
|
|
1 | (1) |
|
Pediatric Clinical Considerations |
|
|
2 | (1) |
|
Adolescent Clinical Considerations |
|
|
3 | (2) |
|
Adult Clinical Considerations |
|
|
5 | (2) |
|
Physiological Considerations for Clinical Testing |
|
|
7 | (1) |
|
|
8 | (3) |
|
|
9 | (2) |
|
On-Site Tests for Therapeutic Drugs |
|
|
11 | (14) |
|
|
Rationale for Therapeutic Monitoring and Need for On-Site Drug Testing |
|
|
11 | (1) |
|
On-Site and Point-of-Care (POC) Drug Testing |
|
|
12 | (1) |
|
Direct On-Site Testing Instruments and Devices for Therapeutic Drugs |
|
|
13 | (2) |
|
Indirect On-Site Testing for Therapeutic Drugs |
|
|
15 | (7) |
|
Monitoring of Lipid Lowering Medications |
|
|
15 | (3) |
|
Monitoring of Antithrombotic Medications |
|
|
18 | (1) |
|
|
18 | (1) |
|
Oral Antithrombotic Therapy |
|
|
19 | (1) |
|
On-Site Testing for Anticoagulant Drugs |
|
|
20 | (2) |
|
|
22 | (3) |
|
|
22 | (3) |
|
On-Site Workplace Drug Testing |
|
|
25 | (12) |
|
|
|
25 | (5) |
|
Conducting On-Site Workplace Drug Testing |
|
|
30 | (3) |
|
The Future of On-Site Workplace Drug Testing |
|
|
33 | (4) |
|
|
34 | (3) |
|
Program Requirements, Standards, and Legal Considerations for On-Site Drug Testing Devices in Workplace Testing Programs |
|
|
37 | (18) |
|
|
|
|
37 | (1) |
|
What Is ``On-Site'' Testing from a Standards Perspective? |
|
|
38 | (2) |
|
Establishing Federal Standards for On-Site Drug Testing |
|
|
40 | (4) |
|
Drug Testing Advisory Board (DTAB) |
|
|
40 | (2) |
|
|
42 | (1) |
|
|
42 | (1) |
|
Collection Device/Test Device |
|
|
42 | (1) |
|
|
42 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
Quality Control/Quality Assurance (QC/QA) |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
44 | (1) |
|
The Legal Requirements for Confirmatory Testing in Private Sector On-Site Testing |
|
|
44 | (2) |
|
The Legal Requirements for a Medical Review Officer in Private Sector On-Site Testing |
|
|
46 | (1) |
|
New Liability Risks of Drug Testing Providers and On-Site Drug Testing-Another Factor in Establishing Standards |
|
|
47 | (4) |
|
|
51 | (4) |
|
|
52 | (3) |
|
On-Site Testing Devices in the Criminal Justice System |
|
|
55 | (12) |
|
|
|
Drug Testing in the Criminal Justice Arena |
|
|
55 | (5) |
|
|
55 | (1) |
|
|
56 | (1) |
|
Use of Noninstrument Drug Testing Devices |
|
|
57 | (3) |
|
Legal Admissibility, Evidentiary Weight, and Due Process |
|
|
60 | (4) |
|
Standards for Admissibility of Scientific Evidence |
|
|
61 | (1) |
|
Cases Addressing the Use of Noninstument Drug Testing Devices |
|
|
62 | (1) |
|
Requirements for Repeat and/or Confirmation Testing |
|
|
62 | (2) |
|
|
64 | (3) |
|
|
64 | (3) |
|
On-Site Testing Devices and Driving-Under-the-Influence Cases |
|
|
67 | (10) |
|
|
|
67 | (1) |
|
On-Site Testing in DUI Cases |
|
|
68 | (7) |
|
|
75 | (2) |
|
|
75 | (2) |
|
Analysis of Ethanol in Saliva |
|
|
77 | (18) |
|
|
|
77 | (2) |
|
Saliva as a Specimen; Saliva Collection; Relationship of Saliva and Blood-Alcohol |
|
|
79 | (3) |
|
|
80 | (1) |
|
Relation of Saliva-Alcohol to Alcohol in Other Body Fluids |
|
|
80 | (2) |
|
Saliva-Alcohol Testing Principles and Procedures |
|
|
82 | (2) |
|
Commercial Saliva-Alcohol Screening Test Devices |
|
|
84 | (3) |
|
|
87 | (4) |
|
|
90 | (1) |
|
Interpretation and Use of Results |
|
|
91 | (4) |
|
|
91 | (4) |
|
Analysis of Drugs in Saliva |
|
|
95 | (16) |
|
|
|
|
Roadside or On-Site Saliva Drug Testing |
|
|
95 | (5) |
|
|
95 | (1) |
|
|
95 | (1) |
|
Cutoff Concentrations in Saliva |
|
|
96 | (1) |
|
|
97 | (1) |
|
|
98 | (1) |
|
|
98 | (1) |
|
|
99 | (1) |
|
|
99 | (1) |
|
|
99 | (1) |
|
Cozart RapiScan Saliva Drug Test System |
|
|
100 | (8) |
|
|
100 | (1) |
|
|
100 | (3) |
|
|
103 | (1) |
|
|
103 | (1) |
|
|
104 | (3) |
|
|
107 | (1) |
|
|
108 | (1) |
|
|
108 | (3) |
|
AccuSign Drugs of Abuse Test |
|
|
111 | (12) |
|
|
|
|
111 | (1) |
|
|
111 | (4) |
|
|
115 | (5) |
|
|
115 | (1) |
|
|
116 | (1) |
|
Performance of AccuSign Slide Test Near the Cutoff |
|
|
117 | (3) |
|
|
120 | (1) |
|
|
120 | (1) |
|
Product Contact Information |
|
|
121 | (2) |
|
|
121 | (2) |
|
The EZ-SCREEN and RapidTest Devices for Drugs of Abuse |
|
|
123 | (20) |
|
|
|
|
|
123 | (1) |
|
|
123 | (7) |
|
|
123 | (2) |
|
|
125 | (1) |
|
Procedure and Interpretation |
|
|
125 | (1) |
|
Performance Characteristics |
|
|
125 | (5) |
|
|
130 | (10) |
|
|
130 | (2) |
|
|
132 | (1) |
|
Procedure and Interpretation |
|
|
133 | (1) |
|
Performance Characteristics |
|
|
133 | (7) |
|
|
140 | (3) |
|
Frontline Testing for Drugs of Abuse |
|
|
143 | (10) |
|
|
|
|
143 | (1) |
|
Test Principle and Test Instructions |
|
|
143 | (2) |
|
|
143 | (2) |
|
|
145 | (1) |
|
Evaluation of the Frontline Tests |
|
|
145 | (5) |
|
Crossreactivity and Cutoff Concentrations |
|
|
147 | (2) |
|
|
149 | (1) |
|
Evaluation of Frontline Tests |
|
|
149 | (1) |
|
|
150 | (3) |
|
|
150 | (3) |
|
Abuscreen ONTRAK Tests for Drugs of Abuse |
|
|
153 | (10) |
|
|
|
153 | (1) |
|
Principle of Abuscreen ONTRAK |
|
|
153 | (7) |
|
|
154 | (5) |
|
|
159 | (1) |
|
|
159 | (1) |
|
|
160 | (3) |
|
The OnTrak TesTcup® System |
|
|
163 | (22) |
|
|
|
163 | (2) |
|
Product Design and Theory of Drug Detection |
|
|
165 | (1) |
|
Analysis Method and Analysis Precautions |
|
|
166 | (2) |
|
|
166 | (1) |
|
|
167 | (1) |
|
Interpretation of Results |
|
|
168 | (2) |
|
Review and Discussion of the Literature |
|
|
170 | (11) |
|
|
170 | (1) |
|
|
170 | (1) |
|
|
170 | (2) |
|
|
172 | (1) |
|
|
172 | (1) |
|
|
172 | (1) |
|
|
173 | (1) |
|
|
173 | (1) |
|
|
173 | (1) |
|
|
173 | (1) |
|
|
174 | (1) |
|
|
174 | (1) |
|
|
175 | (1) |
|
|
175 | (1) |
|
|
175 | (1) |
|
|
176 | (1) |
|
|
176 | (1) |
|
|
176 | (2) |
|
|
178 | (1) |
|
|
178 | (1) |
|
|
179 | (1) |
|
|
179 | (1) |
|
|
179 | (1) |
|
|
179 | (1) |
|
|
180 | (1) |
|
|
180 | (1) |
|
|
180 | (1) |
|
|
180 | (1) |
|
|
181 | (1) |
|
|
182 | (3) |
|
|
182 | (3) |
|
|
185 | (14) |
|
|
|
|
185 | (1) |
|
|
186 | (2) |
|
Instrumentation and Reagents |
|
|
186 | (1) |
|
|
186 | (1) |
|
Clinical Evaluation and Comparative Study |
|
|
187 | (1) |
|
|
187 | (1) |
|
|
188 | (1) |
|
|
189 | (3) |
|
|
192 | (1) |
|
|
192 | (5) |
|
|
197 | (1) |
|
|
197 | (2) |
|
|
197 | (2) |
|
Triage® Device for Drug Analysis |
|
|
199 | (14) |
|
|
|
199 | (1) |
|
|
200 | (6) |
|
|
202 | (1) |
|
|
202 | (1) |
|
|
203 | (3) |
|
|
206 | (1) |
|
Clinical and Laboratory Evaluations |
|
|
206 | (7) |
|
|
209 | (4) |
|
Visualine II™ Drugs-of-Abuse Test Kits |
|
|
213 | (6) |
|
|
|
|
213 | (1) |
|
|
213 | (1) |
|
|
214 | (1) |
|
|
215 | (2) |
|
Management and Clinical Utility |
|
|
217 | (1) |
|
|
218 | (1) |
|
Drugs-of-Abuse Test Devices: A Review |
|
|
219 | (34) |
|
|
|
|
219 | (2) |
|
|
219 | (1) |
|
|
219 | (1) |
|
|
220 | (1) |
|
|
221 | (6) |
|
|
221 | (1) |
|
|
221 | (1) |
|
Interpretation of the Results |
|
|
222 | (3) |
|
|
225 | (1) |
|
Operational Characteristics |
|
|
226 | (1) |
|
|
227 | (26) |
|
|
228 | (1) |
|
Table 2 Amphetamine Test Results vs GC/MS-AOC Study, HHS Cutoffs |
|
|
228 | (1) |
|
Table 3 Amphetamine Test Results vs GC/MS-AOC Study, AOC Cutoffs |
|
|
229 | (1) |
|
Table 4 Cocaine Test Results vs GC/MS-AOC Study, HHS/AOC Cutoffs |
|
|
229 | (1) |
|
Table 5 Opiates Test Results vs GC/MS-AOC Study, HHS Cutoffs |
|
|
230 | (1) |
|
Table 6 Opiates Test Results vs GC/MS-AOC Study, AOC Cutoffs |
|
|
230 | (1) |
|
Table 7 Cannabinoids Test Results vs GC/MS-AOC Study, HHA/AOC Cutoffs |
|
|
231 | (1) |
|
Table 8 Phencyclidine Test Results vs GC/MS-AOC Study, HHS/AOC Cutoffs |
|
|
231 | (1) |
|
Table 9 All Drugs Test Results vs GC/MS-AOC Study, HHS Cutoffs |
|
|
232 | (1) |
|
Table 10 All Drugs Test Results vs GC/MS-AOC Study, AOC Cutoffs |
|
|
232 | (1) |
|
Table 11 Amphetamines Test Results vs GC/MS-HHS Study, HHS Cutoffs |
|
|
233 | (1) |
|
Table 12 Amphetamines Test Results vs GC/MS-HHS Study, AOC Cutoffs |
|
|
233 | (1) |
|
Table 13 Cocaine Test Results vs GC/MS-HHS Study, HHS/AOC Cutoffs |
|
|
234 | (1) |
|
Table 14 Opiates Test Results vs GC/MS-HHS Study, HHS Cutoffs |
|
|
234 | (1) |
|
Table 15 Opiates Test Results vs GC/MS-HHS Study, AOC Cutoffs |
|
|
235 | (1) |
|
Table 16 Cannabinoids Test Results vs GC/MS-HHS Study, HHS/AOC Cutoffs |
|
|
235 | (1) |
|
Table 17 Phencyclidine Test Results vs GC/MS-HHS Study, HHS/AOC Cutoffs |
|
|
236 | (1) |
|
Table 18 All Drugs Test Results vs GC/MS-HHS Study, HHS Cutoffs |
|
|
236 | (1) |
|
Table 19 All Drugs Test Results vs GC/MS-HHS Study, AOC Cutoffs |
|
|
237 | (1) |
|
Table 20 Variation in Test Results for Products Manufactured by the Same Company (from HHS Study, HHS Cutoffs) |
|
|
237 | (1) |
|
Table 21 Product Descriptions, Operation, and Distributor Information, AOC and DWP Studies AOC Study |
|
|
238 | (6) |
|
|
244 | (9) |
|
Sample Adulteration and On-Site Drug Tests |
|
|
253 | (12) |
|
|
|
253 | (2) |
|
|
255 | (2) |
|
|
257 | (4) |
|
|
257 | (1) |
|
|
258 | (1) |
|
|
258 | (1) |
|
|
259 | (1) |
|
|
260 | (1) |
|
On-Site Adulteration Tests |
|
|
261 | (1) |
|
|
262 | (3) |
|
|
262 | (3) |
Index |
|
265 | |